1. Home
  2. XXII vs PPBT Comparison

XXII vs PPBT Comparison

Compare XXII & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$1.04

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.83

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXII
PPBT
Founded
1998
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XXII
PPBT
Price
$1.04
$0.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
190.3K
292.5K
Earning Date
11-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,346,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$136.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.98
N/A
52 Week Low
$0.78
$0.53
52 Week High
$294.98
$5.20

Technical Indicators

Market Signals
Indicator
XXII
PPBT
Relative Strength Index (RSI) 47.06 53.10
Support Level $0.98 $0.78
Resistance Level $1.09 $0.89
Average True Range (ATR) 0.09 0.07
MACD 0.04 0.01
Stochastic Oscillator 83.36 68.67

Price Performance

Historical Comparison
XXII
PPBT

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: